AMEX · THNR
Amplify Weight Loss Drug & Treatment ETF
$25.95+$0.59 (+2.35%)
Amplify Weight Loss Drug & Treatment ETF’s quoted price sits in the upper half of its reported 52-week range, 7.12% below the high.
Loading market information…
AMEX · GEND · USD
Stock price, dividends
Quote as of Oct 30, 2026, 07:01 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Genter Capital Dividend Income ETF’s quoted price sits in the upper half of its reported 52-week range, 0.59% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Genter Capital Dividend Income ETF’s forward annual dividend is $0.43 per share, paid quarterly. The forward yield is 3.1% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
THE COMPANY BEHIND THE TICKER
Under typical market conditions, the Genter Capital Dividend Income ETF (GEND) primarily focuses its investments by allocating a minimum of 80% of its total assets, including any funds obtained through borrowing, to equity securities of U.S. companies that have a well-established history of distributing dividends. Beyond this core allocation, the fund constructs a carefully diversified portfolio typically comprising 25 to 50 individual securities. These holdings are generally spread across a wide array of economic sectors to ensure broad market exposure.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Nov 1, 2026, 06:53 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
KEEP COMPARING
$25.95+$0.59 (+2.35%)
Amplify Weight Loss Drug & Treatment ETF’s quoted price sits in the upper half of its reported 52-week range, 7.12% below the high.
$11.93+$0.38 (+3.26%)
Polen Capital Emerging Markets ex China Growth ETF’s quoted price sits in the upper half of its reported 52-week range, 7.82% below the high.
$30.61+$0.21 (+0.67%)
Westwood LBRTY Global Equity ETF’s quoted price sits in the upper half of its reported 52-week range, 2.27% below the high.
$36.54+$0.12 (+0.34%)
AdvisorShares Hotel ETF’s quoted price sits in the upper half of its reported 52-week range, 4.62% below the high.
$27.20+$0.18 (+0.67%)
AdvisorShares Restaurant ETF’s quoted price sits in the lower half of its reported 52-week range, 13.97% below the high.
$26.23$0.00 (0.0%)
KraneShares 100% KWEB Defined Outcome January 2027 ETF’s quoted price sits in the lower half of its reported 52-week range, 15.32% below the high.
$27.08-$0.44 (-1.6%)
Ocean Park International ETF’s quoted price sits in the lower half of its reported 52-week range, 8.12% below the high.
$25.71$0.00 (0.0%)
Pacer Developed Markets Cash Cows Growth Leaders ETF’s quoted price sits in the upper half of its reported 52-week range, 4.86% below the high.
